Skip to main content
Equibles

DRUG · Bright Minds Biosciences Inc. · Short Interest

Track DRUG — free

Use DRUG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DRUG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$52.69 +2.25 (+4.46%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Market Cap
$519.74M
Shares
9.86M
Volume · Oct 22 221.3K Avg daily vol (3M) 144.42K

Shares sold short and not yet covered, reported twice monthly. Days to cover is the reported short position divided by average daily volume.

Pull short interest history through the short interest API or MCP →

DRUG Latest Reported Short Interest

FINRA reported 882,832 DRUG shares sold short as of the September 30, 2026 settlement date, a decrease of 49,109 shares. Days to cover was 8.46 based on FINRA's reported average daily volume.

Official FINRA short-interest data · share counts are restated for subsequent splits of this listing

DRUG Short Interest Forecast

Equibles' model estimates 889,038 shares sold short for the October 15, 2026 settlement, +0.7% versus the latest reported position, with a likely range of 756,361 to 1,023,695 shares. This model prediction uses FINRA data through October 15, 2026; FINRA's official release is expected October 26, 2026.

Model estimate

Expected Oct 15 short interest

as of Oct 15 Low confidence 49% chance it rises
889,038 +0.7% vs reported
Likely range 756,361 to 1,023,695 The latest estimate appears in the chart below. Official release expected Oct 26. Methodology
Short Squeeze Score
62/100
Short interest 8.9% of shares — P86 Days to cover 8.5 — P88 Price vs VWAP -19.9% — P23 Short-volume trend -5.3% — P32 Short interest change -5.3% — P33 Worst FTD 0.05% of shares — P74

Positioning score 62.3 + catalyst boost 0 (total capped at 100). This is a screening index, not a probability of a squeeze.

Method and coverage limits

Factor percentiles compare eligible primary operating-company stocks reporting short interest at the latest settlement date (2026-09-30). The weighted mean uses short interest 30%, days to cover 20%, price vs VWAP 15%, short-volume trend 15%, short-interest change 10%, and fails-to-deliver 10%. Missing factors redistribute their weight; incomplete coverage is not evidence of low risk. Price, volume, and earnings boosts add 10 each, capped at 20.

Shares outstanding are not free float. Borrow fees, utilization, lendable supply, recalls, and dealer inventory are not measured. Short-sale volume does not measure the change in open shorts; fails to deliver are not a borrow-cost measurement; price vs VWAP does not establish short sellers' entry prices. Earnings can move prices in either direction.

The weights are judgment-based, not calibrated to future squeeze outcomes. The separate options assessment below does not change this universe ranking.

Options positioning & squeeze sensitivity

Nearest expiration after today within 30 calendar days; same-day expirations and later maturities are excluded.

Open interest is incomplete, stale, or dated inconsistently; positioning totals are unavailable.

Open interest has both a buyer and a seller; it does not reveal dealer hedge direction. Gross gamma sums both calls and puts without netting and uses a local 1% price-change approximation. It measures sensitivity, not predicted buying or a squeeze probability.

Assessment prepared 2026-10-23 11:21 UTC. Options model values may come from a cached snapshot; their original computation time is not supplied. Open interest has its own effective date.

1M 3M 6M 1Y 5Y All
Dimensions
  • Add to chart

    • Short Interest History

    Settlement Date Current Position Previous Position Change Days to Cover
    2026-10-30 Scheduled
    FINRA publishes Nov 10
    		 — — — —
    2026-10-15 Scheduled
    FINRA publishes Oct 26
    		 — — — —
    2026-09-30 882,832 931,941 -49,109 8.46
    2026-09-15 931,941 893,571 +38,370 12.00
    2026-08-31 893,571 897,280 -3,709 7.06
    2026-08-14 897,280 890,847 +6,433 5.42
    2026-07-31 890,847 955,805 -64,958 4.05
    2026-07-15 955,805 952,509 +3,296 3.07
    2026-06-30 952,509 817,654 +134,855 3.60
    2026-06-15 817,654 805,672 +11,982 1.34
    2026-05-29 805,672 756,484 +49,188 2.88
    2026-05-15 756,484 751,049 +5,435 3.68
    2026-04-30 751,049 648,636 +102,413 4.34
    2026-04-15 648,636 703,646 -55,010 3.54
    2026-03-31 703,646 529,485 +174,161 4.56
    2026-03-13 529,485 488,136 +41,349 4.02
    2026-02-27 488,136 491,033 -2,897 6.64
    2026-02-13 491,033 524,789 -33,756 3.87
    2026-01-30 524,789 564,277 -39,488 4.37
    2026-01-15 564,277 336,924 +227,353 1.56
    2025-12-31 336,924 307,407 +29,517 1.68
    2025-12-15 307,407 270,495 +36,912 1.97
    2025-11-28 270,495 273,186 -2,691 2.07
    2025-11-14 273,186 233,622 +39,564 1.32
    2025-10-31 233,622 231,038 +2,584 1.39

    Full FINRA short interest reporting calendar

    Showing 1–23 of 23 settlements
    Key facts CIK 1827401 CUSIP 10919W405 13F (30d) 9 filings 9 filers Visit website Investor relations